AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company will participate at Småbolagsdagarna in Stockholm, Sweden, on June 13 at 14:20 CET.
AlzeCure Presents at Aktiespararna’s Smabolagsdagarna on June 13 Read More »
En un mundo cada vez más dependiente de la tecnología y la industria, la disponibilidad de minerales esenciales se ha vuelto crucial para el desarrollo y la sustentabilidad. Sin embargo, la explotación desenfrenada de estos recursos ha llevado a un escenario preocupante: el agot …
Los recursos minerales al borde del agotamiento: Una carrera contra el tiempo Read More »
GE HealthCare Technologies Inc. announced the pricing of the previously announced secondary underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $78.00 per share.
GE HealthCare Technologies Inc. Prices Secondary Offering of 25,000,000 Shares Read More »
Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706, an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting.
Ionis Pharmaceuticals, Inc. announced the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Ionis prices private placement of convertible senior notes – June 08, 2023 Read More »
Immune-Onc Therapeutics, Inc. announced Phase 1 data for IO-202, a first-in-class humanized IgG1 monoclonal antibody targeting Leukocyte Immunoglobulin-Like Receptor B4.
BioArctic AB’s partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril[1] antibody, for the treatment of early Alzheimer’s disease[2] with confirmed amyloid pathology in the brain, to the Ministry of Food and Drug Safety in South Korea.
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer.
EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer Read More »
Innate Pharma SA is pleased to share Sanofi’s news that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.
Akoya Biosciences, Inc. announced the pricing of its public offering of 8,700,000 shares of common stock at a public offering price of $5.00 per share for gross proceeds of approximately $43.5 million, without giving effect to the underwriting discount and commission as well as estimated expenses payable by Akoya.
Akoya Biosciences Announces Pricing of Public Offering of Common Stock – June 08, 2023 Read More »
